BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12065099)

  • 41. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW; Schild SE; Vora SA; Halyard MY
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of IMRT in reducing penile doses in dose escalation for prostate cancer.
    Sethi A; Mohideen N; Leybovich L; Mulhall J
    Int J Radiat Oncol Biol Phys; 2003 Mar; 55(4):970-8. PubMed ID: 12605975
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Risk-adapted androgen deprivation and escalated three-dimensional conformal radiotherapy for prostate cancer: Does radiation dose influence outcome of patients treated with adjuvant androgen deprivation? A GICOR study.
    Zapatero A; Valcárcel F; Calvo FA; Algás R; Béjar A; Maldonado J; Villá S
    J Clin Oncol; 2005 Sep; 23(27):6561-8. PubMed ID: 16170164
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship of ultrasound staging and bilateral biopsy positivity to outcome in stage T1c prostate cancer treated with radiotherapy.
    Liebross RH; Pollack A; Lankford SP; von Eschenbach AC; Zagars GK
    Urology; 1998 Oct; 52(4):647-52. PubMed ID: 9763087
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer.
    Kattan MW; Zelefsky MJ; Kupelian PA; Cho D; Scardino PT; Fuks Z; Leibel SA
    J Clin Oncol; 2003 Dec; 21(24):4568-71. PubMed ID: 14673043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer.
    Zelefsky MJ; Wallner KE; Ling CC; Raben A; Hollister T; Wolfe T; Grann A; Gaudin P; Fuks Z; Leibel SA
    J Clin Oncol; 1999 Feb; 17(2):517-22. PubMed ID: 10080594
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase 1 dose-escalation study.
    Leibel SA; Zelefsky MJ; Kutcher GJ; Burman CM; Kelson S; Fuks Z
    J Urol; 1994 Nov; 152(5 Pt 2):1792-8. PubMed ID: 7933238
    [TBL] [Abstract][Full Text] [Related]  

  • 48. External beam radiotherapy dose response of prostate cancer.
    Pollack A; Zagars GK
    Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1011-8. PubMed ID: 9392538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inverse and forward optimization of one- and two-dimensional intensity-modulated radiation therapy-based treatment of concave-shaped planning target volumes: the case of prostate cancer.
    Corletto D; Iori M; Paiusco M; Brait L; Broggi S; Ceresoli G; Iotti C; Calandrino R; Fiorino C
    Radiother Oncol; 2003 Feb; 66(2):185-95. PubMed ID: 12648791
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer.
    Martinez AA; Gustafson G; Gonzalez J; Armour E; Mitchell C; Edmundson G; Spencer W; Stromberg J; Huang R; Vicini F
    Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):316-27. PubMed ID: 12023135
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Defining the optimal radiation dose with three-dimensional conformal radiation therapy for patients with nonmetastatic prostate carcinoma by using recursive partitioning techniques.
    Horwitz EM; Hanlon AL; Pinover WH; Anderson PR; Hanks GE
    Cancer; 2001 Sep; 92(5):1281-7. PubMed ID: 11571744
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.
    Kollmeier MA; Stock RG; Stone N
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):645-53. PubMed ID: 14529768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer.
    Zelefsky MJ; Kelly WK; Scher HI; Lee H; Smart T; Metz E; Schwartz L; Fuks Z; Leibel SA
    J Clin Oncol; 2000 May; 18(9):1936-41. PubMed ID: 10784635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease.
    D'Amico AV; Renshaw AA; Cote K; Hurwitz M; Beard C; Loffredo M; Chen MH
    J Clin Oncol; 2004 Sep; 22(18):3726-32. PubMed ID: 15365069
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Equivalent biochemical control and improved prostate-specific antigen nadir after permanent prostate seed implant brachytherapy versus high-dose three-dimensional conformal radiotherapy and high-dose conformal proton beam radiotherapy boost.
    Jabbari S; Weinberg VK; Shinohara K; Speight JL; Gottschalk AR; Hsu IC; Pickett B; McLaughlin PW; Sandler HM; Roach M
    Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):36-42. PubMed ID: 19409729
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial.
    Pollack A; Zagars GK; Antolak JA; Kuban DA; Rosen II
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):677-85. PubMed ID: 12377318
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J
    Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy.
    Cheung R; Tucker SL; Dong L; Kuban D
    Int J Radiat Oncol Biol Phys; 2003 Aug; 56(5):1234-40. PubMed ID: 12873666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions.
    Hanks GE; Hanlon AL; Schultheiss TE; Pinover WH; Movsas B; Epstein BE; Hunt MA
    Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):501-10. PubMed ID: 9635695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Outcome and predictive factors for patients with Gleason score 7 prostate carcinoma treated with three-dimensional conformal external beam radiation therapy.
    Anderson PR; Hanlon AL; Horwitz E; Pinover W; Hanks GE
    Cancer; 2000 Dec; 89(12):2565-9. PubMed ID: 11135217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.